[1]首汉蓉,唐 建,黄泽林,等.黄芩汤加减联合补脾益肠丸对溃疡性结肠炎患者Toll样受体4/髓样分化因子88信号通路的影响*[J].陕西中医,2020,(6):750-753.[doi:DOI:10.3969/j.issn.10007369.2020.06.014]
　SHOU Hanrong,TANG Jian,HUANG Zelin,et al.Effect of modified Huangqin decoction combined with Bupi Yichang Wan on signaling pathway of Toll like receptor 4/ myeloid differentiation factor 88 in patients with ulcerative colitis[J].,2020,(6):750-753.[doi:DOI:10.3969/j.issn.10007369.2020.06.014]
点击复制

黄芩汤加减联合补脾益肠丸对溃疡性结肠炎患者Toll样受体4/髓样分化因子88信号通路的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年6期
页码:
750-753
栏目:
临床研究
出版日期:
2020-06-01

文章信息/Info

Title:
Effect of modified Huangqin decoction combined with Bupi Yichang Wan on signaling pathway of Toll like receptor 4/ myeloid differentiation factor 88 in patients with ulcerative colitis
作者:
首汉蓉1; 唐 建1; 黄泽林1; 杨驭红2
1.四川省德阳市人民医院肛肠科(德阳 618000); 2.成都中医药大学(成都610075)
Author(s):
SHOU Hanrong; TANG Jian; HUANG Zelin; et al.
Deyang People's Hospital in Sichuan Province(Deyang 618000)
关键词:
黄芩汤;  补脾益肠丸;  溃疡性结肠炎;  Toll样受体4;  髓样分化因子88;  免疫球蛋白;  炎症因子水平
Keywords:
Huangqin decoction;  Bupi Yichang Wan;  Ulcerative colitis;  Toll like receptors 4;  Myeloid differentiation factor 88;  Immunoglobulin;  Inflammatory factor levels
分类号:
R574.62
DOI:
DOI:10.3969/j.issn.10007369.2020.06.014
文献标志码:
A
摘要:
目的:研究黄芩汤加减联合补脾益肠丸对溃疡性结肠炎(UC)患者Toll样受体4/髓样分化因子88(TLR4/MyD88)信号通路的影响。方法:选取溃疡性结肠炎患者86例,随机数字表法分组,各43例。对照组采用西医常规治疗,观察组在对照组基础上给予黄芩汤加减加补脾益肠丸治疗; 统计两组中医证候疗效及腹胀、腹泻、腹痛、黏液脓血便、里急后重等症状改善时间,并对比两组治疗前后血清免疫球蛋白水平、血清炎症因子及血清TLR4、MyD88水平情况。结果:观察组治疗总有效率90.70%高于对照组72.09%(P<0.05)。观察组腹胀、腹泻、腹痛、里急后重、黏液脓血便改善时间较对照组短(P<0.05)。治疗后观察组IgA、IgG较对照组低(P<0.05)。治疗后观察组血清IL-6、IL-1β、TNF-α水平较对照组低(P<0.05)。治疗后观察组血清TLR4、MyD88水平较对照组低(P<0.05)。结论:黄芩汤加减联合补脾益肠丸治疗UC,临床治疗效果较好,可调节免疫球蛋白水平,其作用机制可能与抑制血清TLR4/MyD88信号通路活化,进而降低炎症因子水平有关。
Abstract:
Objective:To explore the effect of modified Huangqin decoction combined with Bupi Yichang Wan on signaling pathway of Toll like receptor 4/ myeloid differentiation factor 88(TLR4/MyD88)in patients with ulcerative colitis(UC).Methods:86 cases of UC patients in our hospital were selected and grouped by the random number table,43 cases in each group.The control group was treated with conventional western medicine,while the observation group was given modified Huangqin decoction combined with Bupi Yichang Wan on the basis of the control group.The curative effect of TCM Syndrome,and the improvement time of abdominal distension,diarrhea,abdominal pain,mucus stool,rapid and severe symptoms of two groups were recorded.The levels of serum immunoglobulin,serum inflammatory factor and serum TLR4 and MyD88 were compared before and after treatment.Results:Total effective rate of the observation group 90.70% was higher than that of the control group 72.09%(P<0.05).Symptom improvement time,the improvement time of abdominal distension,diarrhea,abdominal pain,mucus stool,rapid and severe symptoms in the observation group was shorter than that in the control group(P<0.05).Serum immunoglobulin:after treatment,the IgA and IgG in the observation group were lower than those in the control group(P<0.05).Serum inflammatory factors,after treatment,serum levels of IL-6,IL-1 β and TNF- α in the observation group were lower than those in the control group(P<0.05).Serum TLR4 and MyD88 content,after treatment,serum levels of TLR4 and MyD88 in observation group were lower than those in control group(P<0.05).Conclusion:Huangqin decoction combined with Bupi Yichang Wan in the treatment of UC patients has significant clinical effect.It can improve the symptoms of the patients and regulate the level of immunoglobulin,which may be related to the inhibition of the activation of signaling pathway of serum TLR4/MyD88 and then the reduction of the level of inflammatory factors.

参考文献/References:

[1] Luo X,Yu Z,Deng C,et al.Baicalein ameliorates TNBS-induced colitis by suppressing TLR4/MyD88 signaling cascade and NLRP3 inflammasome activation in mice[J].Sci Rep,2017,7(1):16374.
[2] Wang X,Li D,Zhang Y,et al.Costus root granules improve ulcerative colitis through regulation of TGF-β mediation of the PI3K/AKT signaling pathway[J].Exp Ther Med,2018,15(5):4477-4484.
[3] 赵 坤,宋 攀,张其奇,等.黄芩汤治疗溃疡性结肠炎疗效的Meta分析[J].中国实验方剂学杂志,2016,22(4):213-217.
[4] 陈 丽,颜春鲁,朱俊燚,等.黄芩汤对溃疡性结肠炎大鼠的治疗作用及机制研究[J].中药材,2016,39(3):652-655.
[5] 袁继云,潘立华,曹家玮.补脾益肠丸治疗腹泻型肠易激综合征临床疗效观察[J].内蒙古中医药,2017,36(5):12-13.
[6] 王建勋.利湿和血汤加减联合补脾益肠丸治疗溃疡性结肠炎48例疗效观察[J].亚太传统医药,2018,14(3):167-169.
[7] 吴英魁.黄芩汤颗粒剂治疗大肠湿热型溃疡性结肠炎[J].中国医药指南,2016,14(21):187-188.
[8] 陈 璐,周中银.溃疡性结肠炎发病机制的研究进展[J].疑难病杂志,2016,15(6):650-654.
[9] 王敦方,王彦礼,王怡薇,等.黄芩汤对溃疡性结肠炎大鼠TLR4/MyD88通路调控作用研究[J].药学学报,2016,51(10):1558-1563.
[10] 中国中西医结合学会消化系统疾病专业委员会.溃疡性结肠炎中西医结合诊疗共识[J].中国中西医结合消化杂志,2010,18(6):416-419.
[11] 国家中医药管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:247-249.
[12] 游小敏.补脾益肠丸辅助治疗慢性溃疡性结肠炎的疗效评价[J].中国处方药,2015,13(5):54-55.
[13] 王立荣.补脾益肠丸治疗溃疡性结肠炎的临床效果观察[J].临床医学研究与实践,2016,14(1):112.
[14] 张声生,赵鲁卿,侯晓华,等.补脾益肠丸治疗腹泻型肠易激综合征的临床随机对照研究[J].中国中西医结合消化杂志,2018,26(3):223-237.
[15] 崔晓丽.补脾益肠丸辅助治疗慢性结肠炎的效果体会[J].黑龙江医药科学,2016,39(3):98-99.
[16] 刘亚萍,陈佩东,曹雨诞.黄芩汤颗粒剂中黄芩苷、甘草酸及芍药苷的含量测定研究[J].中国医药导刊,2017,19(8):804-808.
[17] 陈勇华,曹群奋,洪琼怪,等.黄芩汤辅助柳氮磺吡啶对溃疡性结肠炎患者血清TNF-α及白介素族水平影响研究[J].中华中医药学刊,2017,35(2):500-503.
[18] 王 艳,李俊霞,王化虹,等.溃疡性结肠炎肠道菌群失调与免疫球蛋白水平的相关性[J].实用医学杂志,2016,32(10):1631-1634.

备注/Memo

备注/Memo:
*四川省卫生健康委员会科研课题(18PJ121)
更新日期/Last Update: 2020-06-09